Name
Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Number of Employees Founded (year) Type of Laboratory Areas of Activity
Net Sales Relevant R&D Budget Request for Further Collaborations
›
› › › › › › › › › › ›
›
› ›
›
Boehringer Ingelheim Biopharmaceuticals GmbH Binger Strasse 173 55216 Ingelheim Germany Matthias Reinig +49-6132-77-0 +49-6132-72-0 bioxcellence@boehringer-ingelheim.com www.bioxcellence.com around 52,000 in 2020 1885 in Ingelheim, Germany S1 Focus on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing € 19.6 billion in 2020 € 3.7 billion in 2020 Boehringer Ingelheim BioXcellence™ seeks companies in need of biopharma development and GMP manufacturing services and helps customers to get their products to market on time.
Company profile Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Headquartered in Ingelheim, Germany, it operates globally with 176 affiliates and around 52,000 employees. In 2020, Boehringer Ingelheim achieved net sales of about 19.6 billion euros. Boehringer Ingelheim BioXcellence™ is a leading biopharmaceutical contract manufacturer — a preferred partner providing the entire production chain from DNA to Fill & Finish. With over 35 years of biotechnology experience, more than 5,000 dedicated and highly trained employees, and a global network we have helped our customers to bring 40 biologics to the market. We have also transferred and optimised more than 150 development and manufacturing projects at all stages from our customers to our facilities, as well as within our network. We work with 70% of the world’s Top 20 pharma and many innovative biotech companies in getting the right treatments and therapies to patients.
Wherever you are, we are by your side. Our network of manufacturing facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China. From these sites, we offer our customers first class biopharmaceutical medicines anywhere in the world and the best suited business model and production site for their needs: Global capacity for cell culture: > 290 kL commercial Global capacity for microbials and yeast fermentation: > 12 kL commercial
